Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Mar 9;170(2):293–302. doi: 10.1007/s10549-018-4745-7

Table 4.

Recurrence free survival and overall survival correlation with PD-L1 and stromal tumor infiltrating lymphocytes in patients treated with trastuzumab and non-trastuzumab based chemotherapy

A. Trastuzumab based chemotherapy
Recurrence Free Survival
Overall Survival
Overall Recurrence No recurrence p-value Overall Death No death p-value
(n=110) (n=16) (n=94) (n=115) (n=13) (n=102)
TIL-Str 25 (0-85) 20 (8-45) 25 (0-85) 0.576 25 (0-85) 14 (3-85) 25 (0-80) 0.102
28-8 in tumor 1.7 (0-85) 0.7 (0-11.7) 1.7 (0-85) 0.336 1.7 (0-85) 3.8 (0-66.7) 1.6 (0-85) 0.747
28-8 in TILs 5 (0-91.7) 0.6 (0-26.7) 8.1 (0-91.7) 0.034 5 (0-91.7) 1.9 (0-60) 5.6 (0-91.7) 0.305
22C3 in tumor 0 (0-73.3) 0 (0-0.8) 0.6 (0-73.3) 0.185 0 (0-73.3) 0 (0-51.7) 0 (0-73.3) 0.534
22C3 in TILs 2.5 (0-66.7) 1.3 (0-26.7) 2.5 (0-66.7) 0.606 2.5 (0-66.7) 0 (0-61.7) 2.5 (0-66.7) 0.407

B. Non-Trastuzumab based chemotherapy
Recurrence Free Survival
Overall Survival
Overall Recurrence No recurrence p-value Overall Death No death p-value
(n=72) (n=14) (n=58) (n=76) (n=7) (n=69)

TIL-Str 22 (0-75) 13 (0-50) 25 (5-75) 0.064 22 (0-75) 3 (5-10) 20 (0-75) 0.009
28-8 in tumor 0.8 (0-15) 0 (0-2.7) 0.8 (0-15) 0.083 0.2 (0-15) 0.8 (0-8.3) 0 (0-15) 0.741
28-8 in TILs 0.9 (0-35) 0 (0-11.7) 1.5 (0-35) 0.185 0.8 (0-35) 0.4 (0-1.1) 0.8 (0-35) 0.728
22C3 in tumor 0 (0-10) 0 (0-0.4) 0 (0-10) 0.688 0 (0-13.8) 0 (0-0.1) 0 (0-13.8) 0.39
22C3 in TILs 0 (0-35) 0 (0-18.8) 0 (0-35) 0.925 0 (0-35) 0 (0-0) 0 (0-35) 0.212